Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Psychiatry"
DOI: 10.1038/s41380-022-01546-2
Abstract: after coronavirus-2). A recent systematic review using 57 studies with 250,351 survivors of COVID-19 shows that the median propor- tion of COVID-19 survivors at least 1 PASC (post-acute sequelae of COVID-19) 54% at 1 month… read more here.
Keywords: comments fluvoxamine; term; covid new; fluvoxamine long ... See more keywords